You searched for: c1-esterase inhibitors

15573 results

F06. Specialised Immunology and Allergy Services

Scope This Clinical Reference Group (CRG) covers specialised treatment of certain immunological and allergic conditions. In relation to immunological conditions, this includes primary immunodeficiencies, autoimmune and autoinflammatory disease where there is associated immunodeficiency, complex autoimmune and vasculitic conditions and autoinflammatory syndromes. In relation to allergic conditions this includes severe, complex and/or rare sub-groups. Membership Dr. […]

Policies: Routinely commissioned

A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide. Addition of […]

Clinical Commissioning Policy: Emicizumab as prophylaxis in people with congenital haemophilia A with factor VIII inhibitors (all ages)

This policy document outlines the arrangements for funding of treatment for people with congenital haemophilia A with factor VIII inhibitors.

Emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors (all ages)

NHS England will commission emicizumab as prophylaxis in people with severe congenital haemophilia A without factor VIII inhibitors in accordance with the criteria outlined in this policy.

Business continuity

Information last updated: 10 March 2016 NHS England Business Continuity Management Framework (service resilience) (2013): This document highlights the need for business continuity management in NHS organisations so that they can maintain continuity of key services in the face of disruption from identified local risks. This document replaces the ‘NHS Resilience and Business Continuity Management […]

Prescribed Services CQUIN Scheme: BI1 Improving Hepatitis C Virus treatment pathways through Operational Delivery Networks

This document contains information on the Prescribed Services Commissioning for Quality and Innovation (CQUIN) scheme 2017-19: BI1 Improving Hepatitis C Virus treatment pathways through Operational Delivery Networks.